Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.
- 391 Downloads
The poor prognosis of children with high-grade glioma (HGG) and high-risk neuroblastoma, despite multidisciplinary therapeutic approaches, demands new treatments for these indications. F14512 is a topoisomerase II inhibitor containing a spermine moiety that facilitates selective uptake by tumor cells via the Polyamine Transport System (PTS) and increases topoisomerase II poisoning. Here, F14512 was evaluated in pediatric HGG and neuroblastoma cell lines. PTS activity and specificity were evaluated using a fluorescent spermine-coupled probe. The cytotoxicity of F14512, alone or in combination with ionizing radiation and chemotherapeutic agents, was investigated in vitro. The antitumor activity of F14512 was assessed in vivo using a liver-metastatic model of neuroblastoma. An active PTS was evidenced in all tested cell lines, providing a specific and rapid transfer of spermine-coupled compounds into cell nuclei. Competition experiments confirmed the essential role of PTS in the cell uptake and cytotoxicity of F14512. This cytotoxicity appeared greater in neuroblastoma cells compared with HGG cells but appeared independent of PTS activity levels. In vivo evaluation confirmed a marked and prolonged antitumoral effect in neuroblastoma cells. The combinations of F14512 with cisplatin and carboplatin were often found to be synergistic, and we demonstrated the significant radiosensitizing potential of F14512 in the MYCN-amplified Kelly cell line. Thus, F14512 appears more effective than etoposide in pediatric tumor cell lines, with greater efficacy in neuroblastoma cells compared with HGG cells. The synergistic effects observed with platinum compounds and the radiosensitizing effect could lead to a clinical development of the drug in pediatric oncology.
KeywordsPediatric high grade glioma Neuroblastoma Polyamine transport system F14512 Topoisomerase II inhibitor
This work was supported by funds from Centre Oscar Lambret, IRCL (Institut de Recherche contre le Cancer de Lille) and IRPF (Institut de Recherche Pierre Fabre).
Conflict of interest
Arnaud Pillon, Anna Kruczynski, Nicolas Guilbaud and Christian Bailly are employed by Pierre Fabre Medicaments, where the products F14512 and F17073 were synthesized.
- 2.Ladenstein R, Poetschger U, Luksch R, Brock P, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, Forjaz De Lacerda A, Beck Popovic M, Bician P, Garami M, Trahair T, Pearson A, Valteau Couanet D (2011) Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. J Clin Oncol (Meeting Abstracts) 29 (18_suppl 2)Google Scholar
- 5.Barret JM, Kruczynski A, Vispe S, Annereau JP, Brel V, Guminski Y, Delcros JG, Lansiaux A, Guilbaud N, Imbert T, Bailly C (2008) F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. Cancer Res 68(23):9845–9853CrossRefPubMedGoogle Scholar
- 6.Gentry AC, Pitts SL, Jablonsky MJ, Bailly C, Graves DE, Osheroff N (2011) Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry 50(15):3240–3249PubMedCentralCrossRefPubMedGoogle Scholar
- 9.Kruczynski A, Pillon A, Creancier L, Vandenberghe I, Gomes B, Brel V, Fournier E, Annereau JP, Currie E, Guminski Y, Bonnet D, Bailly C, Guilbaud N (2013) F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity. LeukemiaGoogle Scholar
- 10.De Botton S, Berthon C, Bulabois C, Prebet T, Vey N, Chevallier P (2012) F14512 a novel polyamine-vectorized anti-cancer drug targeting topoisomerase II in adults patients with acute myeloid leukemia (AML): results from a Phase 1 study. EHA 17th Congress, Amsterdam, pp 14–17Google Scholar
- 11.De Botton S, Quesnel B, Audoly L, Bailly C, Brandely-Talbol M, Provendier O, Bahleda R, Soria J (2014) Tackling leukemia: Phase 1 study of F14512 in relapsed or refractory AML patients. 12th International Congress on Targeted Anticancer Therapies, WashingtonGoogle Scholar
- 12.Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, Jones TA, Williams RD, Grigoriadis A, Vassal G, Workman P, Sheer D, Reis RM, Pearson AD, Hargrave D, Jones C (2009) Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS ONE 4(4):e5209PubMedCentralCrossRefPubMedGoogle Scholar
- 19.Guminski Y, Grousseaud M, Cugnasse S, Brel V, Annereau JP, Vispe S, Guilbaud N, Barret JM, Bailly C, Imbert T (2009) Synthesis of conjugated spermine derivatives with 7-nitrobenzoxadiazole (NBD), rhodamine and bodipy as new fluorescent probes for the polyamine transport system. Bioorg Med Chem Lett 19(9):2474–2477CrossRefPubMedGoogle Scholar
- 20.Mouawad F, Gros A, Rysman B, Bal-Mahieu C, Bertheau C, Horn S, Sarrazin T, Lartigau E, Chevalier D, Bailly C, Lansiaux A, Meignan S (2014) The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines. Oral Oncol 50(2):113–119CrossRefPubMedGoogle Scholar
- 21.Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMedGoogle Scholar